Global In Vitro Colorectal Cancer Testing Market by Test Types, Product Pipeline and Forecast to 2020, New Report by iHealthcareAnalyst, Inc.
In Vitro Colorectal Cancer Testing Market by Test Types (Fecal Occult Blood Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Stool Biomarkers Tests , Cologuard, M2-PK Stool Test, Blood Biomarker Tests, ColoSentry, ColoVantage, Epi proColon, mS9), and Product Pipeline (Cologic, Colox, MarCarePlex, MeScore CRC, miRSIGN, PanC – Dx) 2016-2020
Maryland Heights, MO, March 11, 2017 --(PR.com)-- The global in vitro colorectal cancer testing market is estimated to reach USD 800 Million in 2020, growing at a CAGR of 9.1% from 2016 to 2020.
Browse In Vitro Colorectal Cancer Testing Market by Test Types (Fecal Occult Blood Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Stool Biomarkers Tests, Cologuard, M2-PK Stool Test, Blood Biomarker Tests, ColoSentry, ColoVantage, Epi proColon, mS9), and Product Pipeline (Cologic, Colox, MarCarePlex, MeScore CRC, miRSIGN, PanC – Dx) 2016-2020 at https://www.ihealthcareanalyst.com/report/in-vitro-colorectal-cancer-testing-market/
The majority of colorectal cancers begin as benign growths in the lining of the large bowel wall called adenomatous polyps. Over the years (at least ten years), these polyps grow in size and number, thereby increasing the risk that the cells in the polyps will become cancerous and invade the wall and move on to other organs. Approximately two thirds of these cancers are found in the large intestine and one third in the rectum. Early removal of these growths will prevent colorectal cancer from developing in the first place. Hence, identification and removal of polyps are key to preventing the development of colorectal cancer. Screening for colorectal cancer allows for the early detection of cancer when it is highly curable, as well as the detection of growths (polyps) that might eventually become cancer. Currently, two types of FOBT are approved by the Food and Drug Administration (FDA) to screen for colorectal cancer: guaiac FOBT (gFOBT) and the fecal immunochemical (or immunohistochemical) test (FIT, also known as iFOBT).
The global in vitro colorectal cancer testing market segmentation is based on test types (Fecal Occult Blood Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Stool Biomarkers Tests, Cologuard, M2-PK Stool Test, Blood Biomarker Tests, ColoSentry, ColoVantage, Epi proColon, mS9), and Product Pipeline (Cologic, Colox, MarCarePlex, MeScore CRC, miRSIGN, PanC – Dx).
The global in vitro colorectal cancer testing market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020). The global in vitro colorectal cancer testing market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global in vitro colorectal cancer testing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global in vitro colorectal cancer testing market and included in this report are Abbott Molecular, Inc., Alere, Inc, Beckman Coulter, Inc., BioTime, Inc., Epigenomics AG, Quest Diagnostics, Exact Sciences Corporation, Novigenix SA, CML Healthcare, Inc., and Sysmex Corporation.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/in-vitro-colorectal-cancer-testing-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse In Vitro Colorectal Cancer Testing Market by Test Types (Fecal Occult Blood Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Stool Biomarkers Tests, Cologuard, M2-PK Stool Test, Blood Biomarker Tests, ColoSentry, ColoVantage, Epi proColon, mS9), and Product Pipeline (Cologic, Colox, MarCarePlex, MeScore CRC, miRSIGN, PanC – Dx) 2016-2020 at https://www.ihealthcareanalyst.com/report/in-vitro-colorectal-cancer-testing-market/
The majority of colorectal cancers begin as benign growths in the lining of the large bowel wall called adenomatous polyps. Over the years (at least ten years), these polyps grow in size and number, thereby increasing the risk that the cells in the polyps will become cancerous and invade the wall and move on to other organs. Approximately two thirds of these cancers are found in the large intestine and one third in the rectum. Early removal of these growths will prevent colorectal cancer from developing in the first place. Hence, identification and removal of polyps are key to preventing the development of colorectal cancer. Screening for colorectal cancer allows for the early detection of cancer when it is highly curable, as well as the detection of growths (polyps) that might eventually become cancer. Currently, two types of FOBT are approved by the Food and Drug Administration (FDA) to screen for colorectal cancer: guaiac FOBT (gFOBT) and the fecal immunochemical (or immunohistochemical) test (FIT, also known as iFOBT).
The global in vitro colorectal cancer testing market segmentation is based on test types (Fecal Occult Blood Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Stool Biomarkers Tests, Cologuard, M2-PK Stool Test, Blood Biomarker Tests, ColoSentry, ColoVantage, Epi proColon, mS9), and Product Pipeline (Cologic, Colox, MarCarePlex, MeScore CRC, miRSIGN, PanC – Dx).
The global in vitro colorectal cancer testing market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020). The global in vitro colorectal cancer testing market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global in vitro colorectal cancer testing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global in vitro colorectal cancer testing market and included in this report are Abbott Molecular, Inc., Alere, Inc, Beckman Coulter, Inc., BioTime, Inc., Epigenomics AG, Quest Diagnostics, Exact Sciences Corporation, Novigenix SA, CML Healthcare, Inc., and Sysmex Corporation.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/in-vitro-colorectal-cancer-testing-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories